期刊文献+

蔗糖铁治疗维持性血液透析肾性贫血的疗效观察 被引量:3

下载PDF
导出
摘要 目的观察蔗糖铁联合红细胞生成素(EPO)治疗维持性血液透析(MHD)肾性贫血的疗效和安全性。方法 36例肾性贫血患者按随机数字表法分为静脉组和口服组,各18例,两组均给予EPO皮下注射,静脉组加用蔗糖铁100 mg稀释于100 ml生理盐水中于透析结束前30 min静滴,2次/周,直至完成总补铁量,以后每月用蔗糖铁100 mg维持。口服组加用富马酸亚铁颗粒200 mg,3次/d口服。两组均观察12周。结果治疗后两组Hb、红细胞压积、血清铁蛋白、转铁蛋白饱和度均较治疗前明显提高(P均<0.05),静脉组Hb上升幅度明显高于口服组(P<0.01);静脉组疗效好于口服组(P<0.05),不良反应发生率低于口服组(P<0.05)。结论蔗糖铁联合EPO治疗肾性贫血,疗效好、安全性高,可作为MHD肾性贫血患者长期补铁的方法之一。
作者 朱征西
出处 《广西医学》 CAS 2012年第4期447-450,共4页 Guangxi Medical Journal
  • 相关文献

参考文献13

  • 1Portol6s J, L6pez-C6mez JM, Aljama P. A prospective multi- centre study of the role of anaemia as a risk factor in haemo- dialysis patients:the MAR Study [ J ]. Nephrol Dial Trans- plant,2007,22 (2) : 500 - 507.
  • 2Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodi- alysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Prac-tice Patterns Study (DOPPS) [ J ]. Nephrol Dial Transplant, 2004,19(1) :121 -132.
  • 3Hukie F, Nuhbegovic S, Brkic S, et al. Biochemical markers of iron status in hemodialysis patients [ J ]. Med Arh, 2010, 64(4) :219 -222.
  • 4Stepàkov6 S. Anemia and chronic kidney failure [ J ]. Vnitr Lek,2011,57(7 -8) :631 -634.
  • 5Besarab A, Coyne DW. Iron supplementation to treat anemia in patients with chronic kidney disease [ J ]. Nat Rev Neph- rol,2010,6(12) :699 -710.
  • 6陈灏珠.实用内科学[M].第13版.北京:人民卫生出版社,2009:1009-1010.
  • 7National Kidney Foudation-Dialysis Outcomes Quality Initia- tive. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease:Update 2000 [ J ]. American Journal of Kidney Diseases,2001,37 ( 1 Suppl 1 ) : 182 - 238.
  • 8袁群生,郑法雷.静脉应用蔗糖铁纠正功能性缺铁对血液透析患者贫血的作用[J].中国血液净化,2004,3(5):254-260. 被引量:9
  • 9Kanakakom K, Cavill I, Jacobs A. The metabolism of intra- venously administered iron-dextran [ J ]. British Journal of Haematology, 1973,25 (5) :637 - 643.
  • 10徐斌,季大玺,陈月梅,陶静,龚德华,邢昌赢,刘必成,陈江华,张英,邹作君,赵显国,王荣,陈威,姜埃利,刘志红,黎磊石.静脉用蔗糖铁与右旋糖酐铁治疗维持性血液透析肾性贫血患者的多中心临床观察[J].肾脏病与透析肾移植杂志,2008,17(2):123-127. 被引量:27

二级参考文献47

  • 1[28]Cavill I, Macdougall IC. Erythrepoiesis and iron supply in patients treated with erythropoietin. Erythroppoiesis, 1992, 3:50-55
  • 2[29]Eschbach JW, Cook JD, Finch CA. Iron absorption in chronic renal disease. Clin SCi, 1970, 38:191 - 196
  • 3[30]Gokal R, Millard PR, Weatherall DJ, et al. Iron metabolism in haemodialysis patients. Q J Med, 1979, 48: 369-391
  • 4[31]Donnelly SM, Posen GA, Ali MAM. Oral iron absorption in hemodialysis patients treated with erythropoietin. Clin Invest Med, 1991, 14:271- 276
  • 5[32]Valderrabano F. Erythropoietin in chronic renal failure. Kidney Int,1996, 50: 1373- 1391
  • 6[33]amstra RD, Block MH, Schocker A. Intravenous iron dextran in clinical medicine. JAMA, 1980, 243:1726-1731
  • 7[34]Fishbane S, Ungureanu V, Macsaka JK, et al. Safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis, 1996, 28:529- 534
  • 8[35]Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans. Am J Kidney Dis, 1999,33: 464 - 470
  • 9[36]Lawrence R. Development and comparison of iron dextran products.PDAJ Phar Sci Technol, 1998, 52:190- 197
  • 10[37]Roe DJ, Harford AM, Zager PG, et al. Iron utilization after iron dextran administration for iron deficiency in patients with dialysis - associated anemia: A prospective analysis and comparison of two agents. Am J Kidney Dis, 1996, 28:855 - 860

共引文献112

同被引文献26

引证文献3

二级引证文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部